CommuniTech

Communi-T is a French biotechnology company focused on developing innovative immunotherapies for autoimmune diseases by modulating T-cell receptor (TCR) signaling. A spin-off from the University of Strasbourg, the company utilizes a proprietary platform to identify small molecules that can selectively dampen the overactive T-cell responses responsible for tissue destruction in conditions like Type 1 Diabetes and Multiple Sclerosis. Unlike broad immunosuppressants, Communi-T's approach aims to restore immune balance without compromising the body's ability to fight infections. The company's lead programs are currently in the pre-clinical stage, targeting high-unmet-need indications within the autoimmune space.